Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 16/20 | 0.60 |
| ▸ | DRD2 | P14416 | 15/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7994734 | 1.00 | DRD4 (0.60) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL6846749 | 0.91 | DRD4 (0.73) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL7822811 | 0.91 | DRD4 (0.59) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL5417646 | 0.91 | DRD4 (0.73) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL6908454 | 0.89 | DRD4 (0.69) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL7812210 | 0.89 | DRD4 (0.69) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL7998001 | 0.89 | DRD4 (0.69) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL7820625 | 0.88 | DRD4 (0.69) | DRD4DRD2HTR1AHTR2A | |
| SCHEMBL7824302 | 0.86 | DRD4 (0.59) | DRD4DRD2HTR1AHTR2AADORA2A | |
| SCHEMBL7820261 | 0.85 | DRD4 (0.58) | DRD4DRD2HTR1AHTR2AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| EP-0874849-B1 | 2,7-SUBSTITUTED OCTAHYDRO-PYRROLO 1,2-A]PYRAZINE DERIVATIVES | PFIZER (US) | 2001-09-19 | — | — | EP | claimed |
| US-6284757-B1 | ANTISEROTINONE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | claimed |
| EP-0982030-A2 | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands | Pfizer Products Inc. (US) | 2000-03-01 | — | — | EP | claimed |
| EP-0874849-A1 | 2,7-SUBSTITUTED OCTAHYDRO-PYRROLO 1,2-A]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1998-11-04 | — | — | EP | claimed |
| US-5714487-A | 2,7-substituted octahydro-pyrrolo 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-02-03 | — | — | US | claimed |
| WO-1997023482-A1 | 2,7-SUBSTITUTED OCTAHYDRO-PYRROLO[1,2-A]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1997-07-03 | — | — | WO | claimed |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | PFIZER INC | 2002-07-18 | — | — | US | disclosed |
| EP-1213031-A2 | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | Pfizer Products Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | disclosed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-0874849-B1 | 2,7-SUBSTITUTED OCTAHYDRO-PYRROLO 1,2-A]PYRAZINE DERIVATIVES | PFIZER (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6284757-B1 | ANTISEROTINONE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| EP-0982030-A2 | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands | Pfizer Products Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| EP-0874849-A1 | 2,7-SUBSTITUTED OCTAHYDRO-PYRROLO 1,2-A]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5714487-A | 2,7-substituted octahydro-pyrrolo 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-02-03 | — | — | US | disclosed |
| WO-1997023482-A1 | 2,7-SUBSTITUTED OCTAHYDRO-PYRROLO[1,2-A]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094986-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | DRD4 4/4885DRD2 6/4885HTR1A 12/4885 |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | DRD4 31/4885DRD2 35/4885HTR1A 155/4885 |
| US-20040048869-A1 | Combination treatment for depression, anxiety and psychosis | HTR4, CHRNA4, GRM4 | DRD4 4/4885DRD2 6/4885HTR1A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.